Nanoligent closes €12 million Series A financing to advance its lead oncology nanodrug
Nanoligent is proud to announce the completion of a €12 million Series A financing round led by Inveready (Inveready Biotech IV), with participation from CDTI (through the Innvierte program), Clave Capital (Clave Innohealth), and existing investors i&i Biotech Fund I, Italian Angels for Growth / Nanolinvest, and AVANTECA Partners. The proceeds will support completion of […]
